Evaluation of the Quality of the NovoSeven (rFVIIa) Tratment Practice at Rigshospitalet, Copenhagen University Hospital

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Rigshospitalet, Denmark.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00192933
First received: September 13, 2005
Last updated: October 18, 2006
Last verified: September 2005
  Purpose

The purpose is to evaluate and improve NovoSeven treatment practice done according to our guidelines


Condition Intervention
Hemorrhage
Shock
Procedure: NovoSeven treatment according to guideline

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by Rigshospitalet, Denmark:

Study Start Date: January 2000
Estimated Study Completion Date: December 2010
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Indication for NovoSeven treatment according to our guideline

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00192933

Contacts
Contact: Pär Johansson, MD, MPA +45 3545 2030 rh08061@rh.dk
Contact: Jakob Stensballe, MD +45 3545 8269 stensballe@rh.dk

Locations
Denmark
Rigshospitalet, Copenhagen University Hospital Recruiting
Copenhagen, Denmark, DK-2100
Contact: Pär Johansson, MD, MPA    +45 3545 2030    rh08061@rh.dk   
Contact: Jakob Stensballe, MD    +45 3545 8269    stensballe@rh.dk   
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Study Chair: Pär Johansson, MD, MPA Blood Bank, Rigshospitalet, Copenhagen University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00192933     History of Changes
Other Study ID Numbers: 2004-41-3996
Study First Received: September 13, 2005
Last Updated: October 18, 2006
Health Authority: Denmark: Ethics Committee

Additional relevant MeSH terms:
Hemorrhage
Shock
Pathologic Processes

ClinicalTrials.gov processed this record on August 19, 2014